 Prospects use antagonists platelet glycoprotein IIb/IIIa receptor post-angioplasty restenosis thrombosis many advances inception humans coronary angioplasty problems abrupt arterial closure late restenosis Excessive platelet deposition site angioplasty important role pathophysiology problems Monoclonal antibodies venom-derived synthetic peptides common protein recognition sequence platelet glycoprotein IIb/IIIa receptor early stages preclinical clinical testing hold promise abrupt closure restenosis platelet function Whether agents clinical practice effects complex pathophysiology problems safety profile patients likely antithrombotic medications coronary angioplasty